Trial
NCT07123662
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Guangzhou Bio-gene Technology Co., Ltd
Collaborators
—
Condition
Leukemia
Intervention
Gamma-Delta T cell injection
Why stopped
Due to corporate strategic adjustment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-28